PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27417275-13	2017	CONCLUSIONS: Intravitreal dexamethasone treatment resulted in alterations in the concentrations of pro-inflammatory cytokines MCP-1 and IL17-E in patients with BRVO and MCP-1 and IL1-alpha in patients with CRVO.	Dexamethasone	26-39	C-C motif chemokine ligand 2	Homo sapiens	126-131	
27417275-13	2017	CONCLUSIONS: Intravitreal dexamethasone treatment resulted in alterations in the concentrations of pro-inflammatory cytokines MCP-1 and IL17-E in patients with BRVO and MCP-1 and IL1-alpha in patients with CRVO.	Dexamethasone	26-39	interleukin 25	Homo sapiens	136-142	
27417275-13	2017	CONCLUSIONS: Intravitreal dexamethasone treatment resulted in alterations in the concentrations of pro-inflammatory cytokines MCP-1 and IL17-E in patients with BRVO and MCP-1 and IL1-alpha in patients with CRVO.	Dexamethasone	26-39	C-C motif chemokine ligand 2	Homo sapiens	169-174	
27417275-13	2017	CONCLUSIONS: Intravitreal dexamethasone treatment resulted in alterations in the concentrations of pro-inflammatory cytokines MCP-1 and IL17-E in patients with BRVO and MCP-1 and IL1-alpha in patients with CRVO.	Dexamethasone	26-39	interleukin 1 alpha	Homo sapiens	179-188